P. Connolly

发表

Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations

B. Miller, A. Lazaar, J. Bloomer, 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis

Michael D. Urbaniak, David W. Gray, G. Drewes, 2018, Nature.

Use of a gastro-intestinal model and gastroplus[tm] for the prediction of in vivo performance

R. Havenaar, M. Minekus, D. Elder, 2006 .

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

B. Miller, R. Tal-Singer, A. Lazaar, 2015, BMC Pharmacology and Toxicology.

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

B. Miller, A. Lazaar, J. Bloomer, 2014, European Journal of Drug Metabolism and Pharmacokinetics.

Overcoming extractability hurdles of a 14C labeled taxane analogue milataxel and its metabolite from xenograft mouse tumor and brain tissues.

P. Connolly, H. Safarpour, X. Tong, 2009, Journal of pharmaceutical and biomedical analysis.

MRI studies of the hydrodynamics in a USP 4 dissolution testing cell.

A J Sederman, L. Gladden, A. Sederman, 2011, Journal of pharmaceutical sciences.

On-line solution stability determination of pharmaceuticals by capillary electrophoresis

K. Altria, P. Connolly, 1993 .

Predicting the human in vivo performance of different oral capsule shell types using a novel in vitro dynamic gastric model.

M. Wickham, R. Faulks, J. Butler, 2011, International journal of pharmaceutics.